First U.S. sales of Komzifti (ziftomenib) triggers $135 Million milestone payment to Kura Oncology under collaboration and license agreement with Kyowa Kirin
Kura Oncology, Inc. announced the first U.S. commercial sale of Komzifti (ziftomenib) has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa… read more.
